| Price | $1.97 |
| Year Range | $1.5 – $2.52 |
| Market Cap | $275M |
| PE Ratio | 3.47 |
| Industry | Biotechnology |
What Is Inhibikase Therapeutics’s AI Stock Analysis?
Inhibikase Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Inhibikase Therapeutics’s momentum in near-real time.
Inhibikase Therapeutics (IKT) has an AltIndex AI Score of 47/100, currently a Hold signal. The AI Score distills Inhibikase Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Inhibikase Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Inhibikase Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving IKT’s AI Score?
Fundamentals
Net income for the last quarter was $-20M. This represents a decrease of 19.60% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 97.58%, which may be a cause for concern. Ebitda for the last quarter was $-20M. This represents a decrease of 19.60% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 75.45%, which may be a cause for concern. The current P/E ratio is 3.47. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Inhibikase Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.97. This represents a decrease of 15.45% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 22.36%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $1.98, which is lower than the previous SMA10 of $1.98. This suggests a potential downward trend in price movement. The RSI is 40, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Inhibikase Therapeutics is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. Inhibikase Therapeutics has an estimate of 2,000 visitors to their webpage. The number of visitors is down by -60% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Inhibikase Therapeutics’s job postings, web traffic and app downloads.
Frequently Asked Questions: Inhibikase Therapeutics AI Stock Analysis
Inhibikase Therapeutics's AltIndex AI Score is 47/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Inhibikase Therapeutics a Hold (47/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Inhibikase Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the IKT AI Score or sign up to read the full thesis.
